Stem Cell Therapeutics Corp.

Stem Cell Therapeutics Corp.

November 25, 2009 11:10 ET

Stem Cell Therapeutics Corp. Announces Regenerative Medicine Panel Discussion led by Dr. Allen Davidoff

CALGARY, ALBERTA--(Marketwire - Nov. 25, 2009) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT") announced today that Dr. Allen Davidoff, VP of Product Development, will be moderating a meeting and panel discussions as part of a public forum discussing "Demystifying innovations and advancing the commercialization of Alberta's emerging technologies" in Regenerative Medicine.

This public forum will be held in Calgary this evening from 7:00-9:30pm at the Kerby Seniors Centre. The Alberta Council of Technologies ("ABCtech") and BioAlberta will also be co-hosting a second, similar public forum tomorrow evening in Edmonton.

About the ABCTech and BioAlberta Public Forums ( Each of the two public events is designed to engage Albertans in a patient-focused dialogue to demystify stem cell therapies. The forums have been designed to resolve three objectives: 1) to increase public and patient awareness of stem cell therapies, its implications on health care delivery and their potential in preventing and treating degenerative diseases, 2) to establish Alberta's bio-tech sector as a world leader in the development of stem cell technologies, and 3) to prepare Alberta for the early delivery of stem cell therapy.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information